Drug & intervention

darbepoetin alfa

RxCUI 283838

Clinical trials19
Recruiting0
Related conditions20
Synonyms8

Medication research snapshot

CureCurrent currently links 19 distinct registered clinical trials to darbepoetin alfa through its RxNorm intervention mappings. 0 of those studies have the registry status “recruiting” (0%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is Amgen, associated with 13 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is Boston, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most common trial-reported condition associated with this drug concept is Anemia (15 linked trials). A registry intervention association is not proof that a drug is approved or effective for that condition.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Darbepoetin alfa

Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp. The medication was approved in September 2001, by the US Food and Drug Administration for treatment of anemia in patients with chronic kidney failure by intravenous or subcutaneous injection. In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy. Dr. Reddy's Laboratories launched darbepoetin alfa in India under the brand name Cresp in August 2010. This is the world's first follow-on biologic of darbepoetin alfa. Darbepoetin is produced by recombinant DNA technology in modified Chinese hamster ovary cells. It differs from endogenous erythropoietin (EPO) by containing two more N-linked oligosaccharide chains. It is an erythropoiesis-stimulating 165-amino acid protein. It is on the World Health Organization's List of Essential Medicines.

Read on Wikipedia ↗ Wikidata Q2178381 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

19 shown
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney DiseaseNCT01581073 · 2012-02-16
COMPLETED
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyNCT00858364 · 2009-07-17
TERMINATED
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary DiseaseNCT00579046 · 2008-11-01
WITHDRAWN
A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic NephropathyNCT00907608 · 2007-12-01
TERMINATED
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialNCT00534456 · 2007-01-01
TERMINATED
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate CancerNCT00381836 · 2006-10-01
TERMINATED
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialNCT00358215 · 2006-06-01
COMPLETED
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.NCT00327535 · 2006-05-01
COMPLETED
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)NCT00093015 · 2004-08-01
COMPLETED
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & AnemiaNCT00086086 · 2003-08-01
COMPLETED
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerNCT00146562 · 2003-07-01
COMPLETED
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaNCT00119613 · 2002-12-01
COMPLETED
Treatment for Patients Suffering From Anemia Due to ChemotherapyNCT00120692 · 2002-10-01
COMPLETED
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyNCT00120679 · 2002-10-01
COMPLETED
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and AnemiaNCT00117234 · 2002-09-01
COMPLETED
Heart Failure and AnemiaNCT00049985 · 2002-07-01
COMPLETED
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control SubjectsNCT00117247 · 2002-06-01
COMPLETED
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyNCT03776032 · 1999-09-14
COMPLETED
Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesNCT00036023
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.